تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
The Procter & Gamble Company's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $340.1B | |
|---|---|---|
| Revenue (ttm) | 87.9B | |
| Net income (ttm) | 15.7B | |
| EPS (ttm) | $6.64 | |
| Shares out | 2.3B | |
| P/E (trailing) | 23.9x | |
| P/E (forward) | 21.1x | |
| Dividend | $4.35 (2.75%) | |
| Volume | 3,382,574 | |
| Beta | 0.38 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2026-06-30 | Trend |
| Revenue | $80.19B | $82.01B | $84.04B | $84.28B | $87.03B | +2.1% |
| Gross profit | $38.03B | $39.25B | $43.19B | $43.12B | $43.67B | +3.5% |
| Operating income | $17.81B | $18.13B | $18.55B | $20.45B | $19.75B | +2.6% |
| Net income | $14.74B | $14.65B | $14.88B | $15.97B | $16.05B | +2.1% |
| EPS (diluted) | $5.81 | $5.90 | $6.02 | $6.51 | $6.62 | +3.3% |
| EBITDA | $21.24B | $21.77B | $22.58B | $23.92B | $21.25B | +0.0% |
| R&D | $2.00B | $2.00B | $2.00B | $2.10B | $2.10B | +1.2% |
| SG&A | $20.22B | $21.11B | $23.31B | $22.67B | $23.92B | +4.3% |
Recent company headlines from major financial publishers.
The base case is modest compounding, not a sharp reacceleration. A miss against either annual revenue anchor would disconfirm it by FY2028.
Upside requires FY2028 earnings to meet the forecast, FY2026 cash generation to persist, and the FY2024-to-FY2026 decline in diluted shares to continue. A miss against the FY2028 forecast or weaker operating cash would disconfirm this path.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.0% | $151 | $163 | $180 | $204 | $244 |
| 6.0% | $131 | $138 | $146 | $158 | $173 |
| 7.0% | $117 | $121 | $126 | $133 | $141 |
| 8.0% | $107 | $110 | $113 | $117 | $122 |
| 9.0% | $99.4 | $102 | $104 | $107 | $110 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
